<DOC>
	<DOCNO>NCT01335295</DOCNO>
	<brief_summary>Objective study evaluate safety tolerability flavocoxid administer daily oral dose 500 1000 mg/die one year DMD patient , alone association steroid ( deflazacort alternate day ) start least one year . The investigator also perform multidimensional clinical evaluation cover functional muscle strength quality life ( QoL ) assessment .</brief_summary>
	<brief_title>Safety Study Flavocoxid Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>clinical diagnosis DMD , confirm muscle biopsy molecular analysis MPLA ; range age 4 16 year ; unaided ambulation least 75 meter , unassisted Screening 6MWT . Other personal assistance use assistive device ambulation ( eg , short leg brace , long leg brace walker ) permit . followup least 1 year baseline select motor outcome measure ; patient able perform evaluation test ; patient legally authorize representative ( LAR ) able understand give inform consent ; absence contraindication use flavocoxid ( see ) ; write informed consent sign LAR . treatment drug analogue , similar interact flavocoxid immunosuppressive therapy ( corticosteroid ) within 3 month prior start study treatment ; exposure another investigational drug supplement within 2 month prior start study treatment ; presence cognitive impairment could influence performance evaluation test ; history major surgical procedure within 30 day prior start study treatment ; expectation major surgical procedure ( eg , scoliosis surgery ) 12month treatment period study ; ongoing participation therapeutic clinical study ; expectation recruitment forthcoming exon51 trial ; requirement daytime ventilator assistance ; presence liverdiseases assumption hepatotoxic agent ; screen laboratory value laboratory range clinically meaningful ; prior ongoing medical condition ( eg , concomitant illness , psychiatric condition , behavioral disorder , alcoholism , drug abuse ) , medical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could adversely affect safety subject , make unlikely course treatment followup would complete , could impair assessment study result .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Flavocoxid</keyword>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>pilot study</keyword>
</DOC>